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Abstract
Background: Despite increases in HIV testing, only a fraction of people newly diagnosed with HIV infection enter
the care system and initiate antiretroviral therapy (ART) in South Africa. We report on the design and initial
enrollment of a randomized trial of a health system navigator intervention to improve linkage to HIV care and TB
treatment completion in Durban, South Africa.
Methods/Design: We employed a multi-site randomized controlled trial design. Patients at 4 outpatient sites were
enrolled prior to HIV testing. For all HIV-infected participants, routine TB screening with sputum for mycobacterial
smear and culture were collected. HIV-infected participants were randomized to receive the health system
navigator intervention or usual care. Participants in the navigator arm underwent a baseline interview using a
strengths-based case management approach to assist in identifying barriers to entering care and devising solutions
to best cope with perceived barriers. Over 4 months, participants in the navigator arm received scheduled phone
and text messages. The primary outcome of the study is linkage and retention in care, assessed 9 months after
enrollment. For ART-eligible participants without TB, the primary outcome is 3 months on ART as documented in
the medical record; participants co-infected with TB are also eligible to meet the primary outcome of completion of
6 months of TB treatment, as documented by the TB clinic. Secondary outcomes include mortality, receipt of CD4
count and TB test results, and repeat CD4 counts for those not ART-eligible at baseline. We hypothesize that a
health system navigator can help identify and positively affect modifiable patient factors, including self-efficacy and
social support, that in turn can improve linkage to and retention in HIV and TB care.
Discussion: We are currently evaluating the clinical impact of a novel health system navigator intervention to
promote entry to and retention in HIV and TB care for people newly diagnosed with HIV. The details of this study
protocol will inform clinicians, investigators, and policy makers of strategies to best support HIV-infected patients in
resource-limited settings.
Trial registration: Clinicaltrials.gov. unique identifier: NCT01188941.
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The dual epidemics of HIV and TB remain a leading
health care challenge in South Africa [1,2]. Despite rapid
expansion in the availability of antiretroviral therapy
(ART), only about half of HIV-infected individuals are in
care [3]. The period following HIV diagnosis but prior
to ART initiation represents a time of very high mortal-
ity, attributable in part to late TB diagnosis and poor
rates of TB treatment completion [2,4-6]; TB remains
the leading cause of death among HIV-infected individ-
uals [7]. Interventions focused on integrating intensive
TB screening into HIV diagnostic services and improv-
ing linkage to HIV and TB care would be of substantial
benefit in controlling these epidemics.
Previous studies have shown that the paucity of symp-
toms, transportation barriers, stigma, and lack of self-
efficacy and social support are all factors that negatively
affect the likelihood of entering and remaining in HIV
care [8,9]. While most interventions have focused on
retaining patients in care or improving ART adherence
[10-14], few studies have addressed the multiple barriers
faced by HIV-infected individuals before entering care.
A randomized controlled trial of a brief case manager
intervention in the US improved linkage and retention
in care at 12 months [15,16]. However, no randomized
studies of case managers or navigators to improve link-
age to HIV care have been reported from resource-
limited settings with high HIV and TB prevalence.
This paper describes the rationale and the design of a
randomized controlled trial that aims to establish the ef-
ficacy of an in-person and mobile phone-based health
system navigator (HSN) intervention in improving link-
age to HIV and TB care among newly diagnosed HIV-
infected outpatients in Durban, South Africa, and to
evaluate the cost and cost-effectiveness of this interven-
tion. We hypothesize that the HSN intervention will im-
prove linkage to and retention in care for these diseases
and lead to higher rates of ART initiation and TB treat-
ment completion compared to the standard of care.
Methods
Study rationale
The design of this study is grounded in the Andersen
model of health services utilization, which identifies en-
vironmental and patient characteristics that influence
health-seeking behaviors [17,18]. Andersen recognizes
predisposing factors (i.e. demographic characteristics),
enabling factors (factors that represent the actual ability
to obtain care), and perceived needs (symptoms, values,
and knowledge about health and the health care system),
which together determine an individual’s use of the
health care system [17,18]. The goal of the trial is to
evaluate the efficacy of a strengths-based case manage-
ment approach, implemented by HSNs, for effecting
modifiable patient factors that will improve linkage to
HIV and TB care [19].
Study design
The study is a multi-site randomized controlled trial,
known locally as the Sizanani (Zulu for “Help Each
Other”) Trial. Participants were enrolled at four sites in
the greater Durban area. These sites comprised two
hospital-affiliated outpatient departments and two muni-
cipal clinics (e.g. nurse-driven primary health care sites).
All patients were enrolled in the study and randomized
prior to HIV testing to reduce differential acceptance
rates by results of HIV testing. Participants were tested
for HIV and all newly-identified HIV-infected partici-
pants received TB screening. HIV-infected participants
were either in the intervention group, and were assigned
to a HSN, or the control group, the current usual care
in Durban (Figure 1). Nine months following enrollment,
medical records will be reviewed, and all participants
will be contacted by telephone to assess linkage to HIV
care and TB treatment completion. Follow-up for the
study is ongoing.
Randomization
After completing the baseline questionnaire, enrolled
participants were randomized, prior to HIV testing, to
the intervention or the usual care arm. Randomization
was stratified by site and gender, with blocks of varying
length. Randomization assignments were created by
the Boston-based Data Coordinating Center. A
randomization table that was inaccessible to the South
African research assistants was embedded in a Handheld
Assisted Patient Interview (HAPI) device and provided
randomization assignments for consecutive study
numbers.
Setting and participants
Participants were enrolled at four outpatient sites in
KwaZulu-Natal. McCord Hospital predominantly serves
an urban population in the greater Durban area.
McCord was part of the PEPfAR-funded scale-up of
ART from 2004 to 2012. St Mary’s Hospital is a state-
aided district hospital, serving a peri-urban population,
which began offering PEPfAR-funded ART starting in
2003. In addition, participants were enrolled in two pri-
mary health municipal clinics: Mariannridge and
Tshelimnyama. In August 2012, the McCord enrollment
site closed; enrollment continued at the other three sites.
All adults (≥18 years old), English- or Zulu-speaking
were eligible if they met the following criteria: presenting
Monday through Friday for outpatient care, voluntarily
had an HIV test, were able and willing to give informed
consent, reported no prior positive HIV test, were will-
ing to share HIV and TB test results with research staff,
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screening.
Enrollment procedures
Eligible participants signed a consent form (in English or
in Zulu) in a private area, and the research assistant then
administered a baseline questionnaire comprised of de-
tailed demographic information, as well as clinical infor-
mation including depression, social supports and self-
identified barriers to engaging in care. At enrollment,
participants also provided contact details, as well as the
contact information for a family member or friend who
could be telephoned if the participant could not be
reached. Participants were asked their preference for
Zulu or English SMS text. Participants then underwent
counseling and rapid HIV testing by the study sites’ HIV
counseling staff as per standard South African protocol
[20] and received test results immediately. All HIV-
infected participants were counseled regarding the
meaning of the HIV test result, the appropriate next
steps, and how to obtain HIV treatment if needed; they
were offered venipuncture for a CD4 count, and
instructed to return for results approximately two weeks
later. HIV-infected participants were then seen by a
Sizanani nurse who administered a brief standardized
TB symptom questionnaire and obtained history related
to prior and current TB treatment. Participants expecto-
rated a single sputum specimen, spontaneously or using
nebulized 3% hypertonic saline, if needed. Sputum speci-
mens were transported daily to the TB laboratory of the
University of KwaZulu-Natal. All sputum samples were
stained to assess for acid fast bacillus (AFB) smear, and
were processed for Mycobacterium tuberculosis culture
with drug susceptibility testing. The TB nurse contacted
Enter OPD or Mobile Van 
Yes
Yes
No
No
Collect: reason for 
ineligibility 
Collect: reason for 
refusal
Eligible 
Informed Consent 
Enrollment
Baseline Questionnaire 
Randomize
If HIV-infected 
HIV test with HIV counselor 
TB test by nurse 
Intervention Standard of care 
Linkage to HIV care and/or 
TB treatment completion  
at 9 months 
Linkage to HIV and/or TB 
treatment completion 
at 9 months 
Figure 1 Consort diagram of the study design. OPD: outpatient department.
Bassett et al. BMC Infectious Diseases 2013, 13:390 Page 3 of 9
http://www.biomedcentral.com/1471-2334/13/390participants upon receipt of a positive AFB or culture,
and they were directed to the site TB nurse for registra-
tion and TB treatment initiation.
Health System Navigator (HSN) intervention
The HSN provided focused personalized support to pa-
tients in the period immediately following HIV diagno-
sis, with or without an accompanying TB diagnosis, to
improve linkage to care. The HSN sought to identify and
influence modifiable patient factors, including self-
efficacy and social support, through a strengths-based
case management approach [19,21]. The HSN conducted
a brief strengths-based interview to help patients identify
their own assets to overcome barriers to obtaining care.
They were also provided with lists of local HIV and TB
care facilities to assist participants with identifying a
convenient and acceptable care site if the participant did
not want to receive care at the study site. The HSNs
provided their study mobile phone number to partici-
pants, and were available to respond to questions. Lastly,
the HSNs physically showed participants the location
where blood could be taken for a CD4 count, as well as
the location of the HIV clinic. Participants then contin-
ued with their routine care at the study site. Once the
patient left the clinic, the HSN contacted the subject
through regularly scheduled SMS reminders to retrieve
test results and keep appointments, as well as providing
psychosocial support through regular telephone calls
(Table 1). During each telephone contact, the HSN
assessed where participants are on the HIV and TB care
pathway (Figure 2). The HSN downloaded weekly re-
ports from the study database which contains lists of pa-
tients due for SMS and telephone calls. Each SMS was
delivered in the subject’s preferred language and did not
mention the study site, HIV or TB. The content of the
SMS was standardized, but the message was dictated by
the subject’s position in the care pathway. For example,
if blood for a CD4 count had been taken, but the subject
had not yet picked up the results, the SMS read
“Sizanani: please pick up results in the next week.” All
patient contacts and the time required for attempted
patient contacts were logged daily by the HSN to allow
for an assessment of the personnel time required to per-
form the intervention.
Usual care
Patients randomized to the usual care arm were given a
date and time to return two weeks later to receive their
CD4 count results from the HIV counselors. As in the
intervention arm, patients with a positive HIV test were
redirected to the TB focal point at each site. A trained
study nurse administered a brief questionnaire regarding
TB symptoms and collects a sputum specimen. Patients
then proceeded to the clinician, where they resumed
their usual care. The participants in the usual care arm
had no further contact with the study staff until the 9-
month follow-up phone call.
Research personnel training
The study staff included a project manager, one enrolling
research assistant at each site, one HSN at each site, one
TB nurse at each site, two follow-up research assistants,
and two data entry personnel. Training was conducted
by a team consisting of the principal investigator, a be-
havioral scientist, a Durban-based social worker, and the
head of the Data Coordinating Center, and included lec-
tures, question/answer, information-sharing, interactive
problem solving and role plays. Some training was com-
mon to all study staff. TB nurses received training in
universal precautions and safe handling of sputum speci-
mens. The HSNs, experienced counselors with more ad-
vanced education, received training in strengths-based
case management [19]. HSNs were provided with stan-
dardized definitions of patient barriers (for example,
competing needs, transportation, fear) and strengths (for
example, self-efficacy, familial emotional support, spir-
ituality) assessed at each patient contact. In addition,
HSNs were given scripts and probes to prepare for their
encounters with patients. The staff also received training
in the ethical conduct of research and confidential hand-
ling of data from the principal investigator and the NIH
online course on the protection of human research par-
ticipants [22].
Follow-up process
Outcomes regarding successful linkage to each step on
the HIV and TB care path are ascertained through re-
view of medical records and registers at the study sites.
In addition, external sources are used, including TB out-
comes from the Department of Health as well as deaths
as ascertained through the South African death registry.
Finally, all participants, regardless of study arm, are
contacted by telephone for a follow-up questionnaire,
with a minimum of 3 call attempts starting at 9 months
and finishing 12 months post-enrollment. The purpose
Table 1 Health System Navigator (HSN) phone call and
SMS schedule
Week Number Post-Enrollment
1 1.5 3 4 6 8 12 16
Type of Contact* SMS XX X X
Phone XX
† XXX ‡
*If participants are not reached at the time of a telephone call, the contact
schedule is intensified by turning the next designated SMS reminder into a
phone call. For example, if a subject is not reached at the week 1 phone call,
the week 1.5 SMS becomes a phone call. The contact schedule differs slightly
by study site, based on the site-specific time to return for CD4 count results.
†HSN calls subject’s alternative contacts if the subject is still unreachable.
‡ Participants are considered unreachable if the HSN still cannot contact them.
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information regarding HIV care obtained outside of the
study sites, as well as changes in family composition,
emotional health, social support, and barriers to care
compared to enrollment.
Outcome measures
Primary outcomes
The primary outcome of the study is linkage to and re-
tention in care assessed 9 months after enrollment for
those HIV-infected individuals eligible for ART or TB
treatment. The primary outcome is defined as: 1)
3 months on ART for ART-eligible HIV-infected pa-
tients, and 2) 6 months of TB treatment or 3 months on
ART for HIV-infected patients co-infected with TB.
Thus, for co-infected patients, a patient who links to ei-
ther HIV or TB treatment is considered to have success-
fully reached the primary outcome. In the primary
analysis, we will use data obtained from medical record
review and TB treatment outcomes as documented by
the Department of Health to minimize ascertainment
bias in the navigator arm. HIV care received outside of
the study sites will be assessed through self-report and
will be used in sensitivity analyses.
Secondary outcomes
HIV-infected participants who are not eligible for ART
or TB treatment at baseline cannot reach a primary out-
come, but may reach a secondary outcome. We will
examine mortality at 9 months, receipt of CD4 count re-
sults, receipt of TB laboratory results, attending ART lit-
eracy training for eligible participants, and repeat CD4
count for ART-ineligible participants at 6 months after
enrollment as secondary outcomes. We hypothesize that
people in the intervention group will be more likely to
undergo CD4 count testing and retrieve their CD4 count
and TB results.
Secondary outcomes will be derived from data col-
lected via medical record review and participant 9-
month follow-up interviews. Family members who an-
swer a deceased subject’s telephone will be queried re-
garding date and cause of death, if known. A list of
reported deaths and all unreachable patients will be
cross-referenced with the South African death registry
using South African identification numbers. Participants
will be considered lost to follow-up if they or their fam-
ily were unreachable by the study staff and do not ap-
pear in the national death registry.
Sample size
Based on our prior work at McCord and St. Mary’s Hos-
pitals, we estimated the HIV prevalence to be 35%
among enrollees, with approximately 20% of HIV-
infected enrollees co-infected with TB [23-25]. Based on
the ART-eligibility criteria at the start of the study, we
anticipated that 22% of enrolled participants would be
eligible to meet a primary outcome. Based on our prior
work, we expected 35% of HIV infected/TB negative pa-
tients in the control group to achieve the primary out-
come. Our power considerations were based on the
assumption that the intervention will affect HIV and TB
treatment outcomes similarly, which we thought reason-
able given the lack of data on linkage to care interven-
tions that distinguish between these groups. The study
was originally powered (90%) to detect a 27% increase in
linkage to care in the intervention arm. We planned to
enroll 4,745 participants in total, with 1,661 HIV-
infected individuals eligible to reach the study outcome.
In June 2012, the McCord Hospital HIV clinic closed
due to the conclusion of PEPfAR funding, thus we
ceased enrollment at the McCord outpatient department
TB-
infected 
Start TB 
treatment
Receive
test result 
Complete
treatment
Drop off 
treatment
Restart
treatment
Not ART 
eligible 
ART 
eligible 
HIV-
infected 
CD4 result/ 
assessment 
CD4 count 
obtained 
ART
training
Start ART   3 months 
on ART
Repeat
CD4  
CD4 result/ 
assessment  
Figure 2 HIV and TB care pathways. ART: Antiretroviral therapy; TB: tuberculosis.
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outcome at the enrollment site. We redeployed the
McCord team to Mariannridge Clinic beginning in Au-
gust 2012. Additionally, with the approval of the trial
DSMB, we used actual trial data on HIV prevalence and
the proportion who receive a CD4 count to refine our
sample size requirements. The updated sample size
called for an additional 149 patients, for a new total of
4,894 participants, 1,714 of whom are HIV-infected.
Data collection
For HIV-related outcomes, the following data elements
are collected: dates and results of HIV test, CD4 count
and viral loads if available, dates of ART training, and
ART initiation. Data are obtained from electronic and
paper records, as well as patients’ self-report (Table 2).
Data on mortality will be obtained from clinical records,
follow-up telephone contacts, and the national death
registry.
For TB outcomes, the site of TB treatment, date of TB
treatment initiation, date of TB treatment completion,
date of assigned treatment outcome, and treatment out-
come (cured, treatment completed, treatment defaulted,
treatment failure, death) will be collected from study site
TB registers as well as from the Department of Health’s
TB outcomes database.
Information on research personnel resource utilization
will be collected, such as the HSN time spent in face-to
face contact with patients, sending SMS, and telephon-
ing participants. This will be used to inform an antici-
pated cost-effectiveness analysis. Table 2 provides a
complete list of data collection tools.
Analysis plan—primary and secondary outcomes
The primary analysis will use the intent to treat ap-
proach. All randomized participants eligible to meet a
study outcome will be analyzed according to the arm
they were assigned to evaluate the efficacy of the naviga-
tor intervention. This analysis will include those whose
outcome cannot be ascertained at follow-up. We will as-
sume conservatively that participants who cannot be
found by study personnel and who do not have data
available in the medical record were not linked to care.
The first phase of the analysis will evaluate the success
of randomization in distributing baseline characteristics
evenly between the intervention and the usual care arms.
Baseline characteristics that are not balanced across the
study arms will be advanced into regression models,
evaluating the efficacy of the intervention, to address
possible confounding. Characteristics that are balanced
but that have an association with the outcome will also
be advanced to final models to reduce error variance. To
evaluate the hypothesis that the intervention will im-
prove linkage rates, we will use adjusted logistic regres-
sion modeling to determine successful linkage to care.
Secondary outcomes will be analyzed in a similar
fashion.
We will conduct a series of hypothesis-generating sec-
ondary analyses to examine the potential impact of sev-
eral predisposing (age, gender), enabling (social support,
self-efficacy), and perceived need factors (reason for HIV
testing) from the Andersen model [17,18] as moderators
and mediators of the intervention. We will build several
logistic regression models, one at a time, with inter-
action between study arm and age, gender, social sup-
port scale and reason for HIV testing, due to capped
Table 2 List of study instruments, data elements and source of information
Data collection
instruments
Time of ascertainment Data collected Source
Pre-screen
checkpoints
Day of enrollment Basic demographic information and eligibility assessment Subject self report
Screening and
baseline
questionnaire
Day of enrollment Demographic information, emotional health, social support,
barriers and competing needs to care
Subject self-report
Contact information Day of enrollment Contact information to reach subject, including preferred
language for SMS
Subject self-report
TB nurse
questionnaire
Day of enrollment TB symptoms and TB treatment history Subject self-report
Health system
navigator contact log
Day of enrollment and
throughout
Perceived barriers to care and strengths to overcome barriers,
time spent contacting participants
Medical record, subject
self-report
Participant log Day of enrollment and
throughout
HIV test and CD4 results and retrieval, ART initiation, TB
treatment dates and outcomes, date last seen
Medical record, death
registry, subject self-report
9-month follow-up
form
Patient telephone interview
9-mo after enrollment
HIV and TB care, demographic and clinical updates, emotional
health, social support, and competing needs
Subject self-report
Study completion
form
At 9-mo follow-up Study endpoint (death, loss to follow-up, completed follow-up) Medical record, HSN log,
death registry
TB: Tuberculosis; HSN: Health system navigator.
Bassett et al. BMC Infectious Diseases 2013, 13:390 Page 6 of 9
http://www.biomedcentral.com/1471-2334/13/390sample size. These analyses will demonstrate whether
the intervention is differentially more efficacious in par-
ticular patient subgroups. If the intervention is effica-
cious in improving linkage to care, we will perform
additional analyses that attempt to identify the mechan-
ism of intervention effect, for example, whether the
intervention improves social support and self-efficacy,
and whether these improvements enhance linkage to
care. This hypothesis-generating analysis will be valuable
for determining whether future studies of this interven-
tion should target particular patient subgroups and
whether certain effects of the intervention (e.g. improve-
ment in self-efficacy) are especially integral to interven-
tion efficacy.
Ethics
Prior to trial initiation, investigators obtained approval
for all study components from the McCord Hospital
Medical Research Ethics Committee, the St. Mary’s Hos-
pital Research Ethics Committee and the Partners Insti-
tutional Review Board (Protocol 2011-P-001195, Boston,
MA). After the closure of the McCord study site, the
McCord Hospital Medical Research Ethics Committee
transferred the protocol to the University of KwaZulu-
Natal Biomedical Research Ethics Committee (BREC).
Questionnaires and consent forms were created in Eng-
lish, translated into Zulu, and back-translated; all trans-
lations and back-translations were submitted for Ethics
Committee review. Potential risks of participation in this
study are minimal to moderate. The risk of stress and
anxiety due to discussion about HIV, HIV testing, and
disclosure of HIV status is minimized by conducting all
discussions in a private space. Recruitment prior to HIV
testing also reduced the burden on the participant.
There is a risk of breach of confidentiality due to shared
cell phone use. To reduce this risk, SMS intentionally
contain no patient identifiers, and do not refer specific-
ally to HIV, TB, or the study site. None of the informa-
tion collected through this investigation will likely affect
a subject’s relationship with other individuals (e.g.,
patient-physician, family relationships) or influence the
subject’s HIV treatment at the research site. All data are
protected in locked cabinets or in password-protected
computers equipped with anti-virus software.
Enrollment results
Enrollment
Enrollment began on August 11, 2010 and ended on
January 16, 2013. Of 6,536 individuals screened, 4,954
(76%) met eligibility criteria; of those 4,903 (99%) were
enrolled over 29 months. In total, 1,546 people were en-
rolled at McCord (enrollment stopped at this site on Au-
gust 6, 2012), 2,188 at St Mary’s, and 1,169 at the two
primary health clinics. Overall, 39% of the participants
enrolled were HIV-infected (range: 30%–51%, depending
on the enrollment site), for a total of 1,899 HIV-infected
participants. As of July 15, 2013, 1,680 participants had
available TB sputum culture results and 216 had no spu-
tum sample available. Of those with culture results, 377
(22%) were identified as actively TB-infected by smear
and/or culture.
Follow-up
Follow-up and outcome ascertainment is ongoing, and
remains blinded to follow-up rates and outcomes across
arms. As of July 15, 2013, 114 participants (6%) had not
yet reached their 9-month assessment; 52 participants
(3%) were due for their 9-month follow-up. 1,329 (70%)
participants had completed their 9-month; 252 partici-
pants (13%) had died or withdrawn. Overall, this yields a
90% follow-up rate (87-90%) at the current time.
Discussion
Innovative strategies are urgently needed to improve
linkage to TB and HIV care, so that South Africans can
reap the maximum benefits from currently available life-
saving therapies. Although HIV testing efforts have ex-
panded recently in South Africa [26], a substantial pro-
portion of people newly diagnosed with HIV are not
retained in the care system [24,27-30]. While evidence
supports that behavioral and cognitive interventions can
be effective for improving ART adherence in sub-
Saharan Africa [31,32], few studies have rigorously eval-
uated approaches for increasing linkage to HIV care in
high-prevalence regions [31].
The Sizanani Trial is unique in its well-articulated
conceptual framework and its focus on the period imme-
diately following HIV diagnosis. The Sizanani interven-
tion includes an initial in-person strengths-based case
management session with a HSN, followed by both SMS
reminders and individualized phone support [15,16,19].
Phone calls and SMS reminders are tailored to each par-
ticipant’s stage on the HIV or TB care pathway, so that
content is maximally relevant. The study focuses on im-
proving both HIV and TB outcomes, given the deadly
synergy between these diseases [33,34]. Participants are
enrolled prior to their HIV test to reduce differential ac-
ceptance rates by results of HIV testing, facilitating a
representative sample of newly diagnosed individuals.
The study enrollment rate is very high (99%), similar to
a study of SMS reminders for ART adherence in Kenya
[10], which may reflect participants’ perception of im-
proved access to care through participation in research
[35].
Understanding better ways of linking and retaining
HIV-infected people in care has become increasingly ur-
gent in light of changing priorities in HIV treatment and
prevention initiatives. Test and treat programs cannot be
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the value of testing is substantively reduced if newly di-
agnosed individuals do not successfully initiate ART to
improve their own health. Similarly, retaining patients in
care and rapidly initiating them onto treatment is crucial
for decreasing HIV transmission for “treatment as pre-
vention” [31,38,39]. If the health system navigator inter-
vention is efficacious, this may represent an important
adjunct to biomedical interventions for decreasing sec-
ondary transmissions. One mathematical simulation
study of HIV testing and treatment strategies in South
Africa found that improving linkage to and retention in
care was associated with a 55% lower rate of new infec-
tions compared to universal testing and treatment alone
[36]. If the HSN is effective at improving linkage to HIV
and/or TB care, we will be uniquely poised to evaluate
the cost, cost-effectiveness, and long-term clinical im-
pact of the intervention.
This design has several limitations. We assume that
the majority of participants link to care at the four study
sites where medical records will be reviewed. However,
participants could enter care at other clinics offering
HIV care in Durban. This problem was exacerbated
when the McCord enrollment site closed, and partici-
pants enrolled there were required to seek HIV care
elsewhere. We are actively evaluating their outcomes.
Specifically, we are determining how many McCord HIV
clinic patients were successfully transferred to another
clinic [40]. In addition, the use of self-report introduces
some reporting bias; however, the primary analysis will
be based on outcomes obtained using medical records,
clinic registers, TB outcomes reported to the Depart-
ment of Health, and the national death registry.
Despite the increasing availability of ART for HIV-
infected individuals in South Africa, patients continue to
access care very late and suffer from extremely high
rates of mortality early after diagnosis. A substantial pro-
portion of those diagnosed with HIV never link to HIV
care and therefore fail to gain access to the personal and
public health benefits of HIV and TB treatment. Yet lit-
tle is known about how best to target patient- and
contextual-level interventions to improve access to care.
This trial has the potential to inform physicians, govern-
ment, and policy makers on how to maximize the bene-
fits of both ART and TB treatments through a strategy
of timely and integrated HIV and TB diagnosis and link-
age to care.
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